SEC ownership of BiomX Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001739174.

Comparable stake leader

T3 Defense Inc.

Disclosed value leader

OrbiMed Israel BioFund GP Limited Partnership

Comparable rows

21/39

Latest evidence

10 Apr 2026

Top shareholders Insider holders Latest transactions

Symbol: PHGE on NYSE
SEC evidence covered: 13D/G, 3/4/5, and 13F
Largest SEC-reported holder: T3 Defense Inc.
Latest 13D/G holder: T3 Defense Inc.
Latest parsed evidence date: 10 Apr 2026
CIK: 0001739174
Location: Dover, DE

Ownership snapshot

Top shareholders of BiomX Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

T3 Defense Inc.

Disclosed value leader

OrbiMed Israel BioFund GP...

Comparable rows

21/39

Latest evidence

10 Apr 2026

13D/G 3/4/5 13F Lead comparable stake: 20% 18 rows are not safely comparable across share classes. 13D/G row: T3 Defense Inc. Showing 1-8 of 39 holder rows.

Quick read

T3 Defense Inc. leads the comparable SEC ownership view at 20%.

21 of 39 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Comparable ownership Top 5

T3 Defense Inc. 20%

Reuven Yeganeh 20%

Cystic Fibrosis Foundation 10%

Nantahala Capital Management, LLC 10%

James E. Flynn 8.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 39 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
T3 Defense Inc.	13D/G Menachem Shalom 13D/G	20%	— 1,600,000 shares	$0	10 Apr 2026
Reuven Yeganeh	13D/G 13D/G	20%	$99,170 381,422 shares	$0	26 Dec 2025
Cystic Fibrosis Foundation	3/4/5 13D/G 10%+ Owner 3/4/5 13D/G	10% from 13D/G	$1,663,688 11,131,426 shares mixed-class rows	—	26 Feb 2025
Nantahala Capital Management, LLC	13F 13D/G Company 13F 13D/G	10% from 13D/G	$430,940 114,795 shares	—	31 Mar 2026
James E. Flynn	3/4/5 13D/G Director, *Director by Deputization · Deerfield Management Company, L.P. 3/4/5 13D/G	8.1% from 13D/G	$2,321,016 5,831,350 shares mixed-class rows	—	21 Apr 2025
Centaurus Investments Ltd	13D/G Rodney Hodges 13D/G	5.2%	— 82,618 shares	$0	31 Mar 2026
Alyeska Investment Group, L.P.	13D/G 13D/G	2.5%	$9,926 38,176 shares	-$592,254	31 Dec 2025
OrbiMed Israel BioFund GP Limited Partnership	3/4/5 13D/G 10%+ Owner · ORBIMED ISRAEL GP LTD. 3/4/5 13D/G	1% from 13D/G	$5,250,517 13,777,980 shares mixed-class rows	—	15 May 2024

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$8,250,000.

Buys

Insiders: 0

Sells

$8,250,000

Insiders: 1

Net

-$8,250,000

Shares: -1,650,000

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 0 Shares: 1,650,000

Window (months)	Sell shares	Buy value	Sell value	Net value
0-3	1,650,000	$0	$8,250,000	-$8,250,000
3-6	0	$0	$0	$0
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 25 reporting-owner rows connected to BiomX Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

OrbiMed Israel BioFund GP Limited Partnership

Net 12M change

-$8,250,000

Latest report

16 Mar 2026

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
OrbiMed Israel BioFund GP Limited Partnership	10%+ Owner	$5,250,517			Filing P/S	15 May 2024
James E. Flynn	Director, *Director by Deputization	$2,321,016			Mixed	21 Apr 2025
Cystic Fibrosis Foundation	10%+ Owner	$1,663,688			Mixed	26 Feb 2025
Chidozie Ugwumba	Exit Form 4 - former 10% owner	$1,018,989			Mixed	17 Oct 2022
Jonathan Eitan Solomon	Chief Executive Officer, Director	$72,246			Mixed	14 Apr 2025
Merav Bassan	Chief Development Officer	$45,370			Mixed	14 Apr 2025
Marina Wolfson	Chief Financial Officer	$39,070			Mixed	14 Apr 2025
Assaf Oron	Chief Business Officer	$9,836			Mixed	16 Sep 2024
Paul J. Sekhri	Director	$4,250			Mixed	28 Jul 2021
Reuven Yeganeh	Director, 10%+ Owner	$0	-$8,250,000	-100%	Mixed	16 Mar 2026
Gbolahan Amusa	Director				Mixed	29 Mar 2022
Thomas Layton Walton	10%+ Owner				Mixed	31 Dec 2021
Dambach Michael E.	Director				Mixed	21 Aug 2023
Jonas Grossman	Director				Mixed	29 Mar 2022
Susan Blum	Director				Mixed	14 Apr 2025
Liat Cohavi Bidas	Director				Mixed	13 Feb 2026
Gregory Louis Merril	Director				Mixed	14 Apr 2025
Marks Jason M.	Director				Mixed	21 Aug 2023
Avraham Gabay	Interim CFO				Mixed	06 Dec 2023
Russell Greig	Director				Mixed	14 Apr 2025

Recent insider transactions for BiomX Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares owned	Date	Ownership
Reuven Yeganeh	PHGE	Common Stock, $0.0001 par value per share	Sale	-100%	$2,650,000	$5.00	-530,000	0	17 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Common Stock, $0.0001 par value per share	Conversion of derivative security				530,000	530,000	17 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Series Y Convertible Preferred Stock	Conversion of derivative security	-100%			-1,060	0	17 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Common Stock, $0.0001 par value per share	Sale	-100%	$2,250,000	$5.00	-450,000	0	16 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Common Stock, $0.0001 par value per share	Conversion of derivative security				450,000	450,000	16 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Common Stock Purchase Warrants	Sale	-100%			-5,000,000	0	16 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Series Y Convertible Preferred Stock	Conversion of derivative security	-45.9%			-900	1,060	16 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Common Stock, $0.0001 par value per share	Sale	-100%	$1,850,000	$5.00	-370,000	0	13 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Common Stock, $0.0001 par value per share	Conversion of derivative security				370,000	370,000	13 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Series Y Convertible Preferred Stock	Conversion of derivative security	-27.4%			-740	1,960	13 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Common Stock, $0.0001 par value per share	Sale	-100%	$1,500,000	$5.00	-300,000	0	12 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Series Y Convertible Preferred Stock	Conversion of derivative security	-18.2%			-600	2,700	12 Mar 2026	Pyu Pyu Capital LLC
Reuven Yeganeh	PHGE	Common Stock, $0.0001 par value per share	Conversion of derivative security				300,000	30,000	11 Mar 2026	Pyu Pyu Capital LLC

^* marks a reported price that did not pass the local price check.